A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs).
MTD or OBD will be determined by the number of participants experiencing dose-limiting toxicities. Safety profile will be assessed through number of participants experiencing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, and physical examinations.
90 days after the last dose of MEDI4736
Ramy Ibrahim, MD
United States: Food and Drug Administration
|Research Site||Boca Raton, Florida|
|Research Site||Albany, Georgia|
|Research Site||Albany, New York|